Ovid Therapeutics Inc. (OVID): Nasdaq/NYSE listing notice — Ovid Therapeutics receives Nasdaq deficiency notice for bid price below $1.00

Ovid Therapeutics Inc.

Received Nasdaq notice on Feb 10, 2025, that average closing bid price was below $1.00 for 31 consecutive trading days.
Company has 180 days, until Aug 11, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.
No immediate impact on listing; common stock continues to trade on Nasdaq while options to cure are explored.
If not cured by Aug 11, Ovid may seek a second 180-day period by transferring to Nasdaq Capital Market.
Failure to cure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 31 consecutive trading days (the “Notice”), as required for continued listing on the Nasdaq under Rule 5450(a)(1) of the Nasdaq’s Listing Rules (the “Rules”). The Notice has no immediate impact on the listing of the Company’s common stock, which w

View on SEC.gov

Browse all listing & compliance notices →

Ovid Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-026192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.